BioNexus Gene Lab pricied of its public offering of 1.25M shares of common stock at a price of $4.00 per share. Network 1 Financial Securities is acting as the sole book-running manager for the offering. BioNexus is developing non-invasive liquid biopsy tests for the early detection of disease risks in the Southeast Asia region.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BGLC: